Denmark’s economy saw a significant boost in the third quarter of this year, recording its fastest growth in nearly four years. The 2.3% GDP increase was largely driven by the pharmaceutical sector, especially the success of Novo Nordisk‘s diabetes and weight-loss drugs, Ozempic and Wegovy. While this growth offers a luminous spot for the Scandinavian nation-a key player in Europe’s pharmaceutical landscape-analysts are also examining the risks of over-reliance on a single industry and increasing competition from U.S.-based firms.
Denmark’s economy experienced its fastest quarterly growth in nearly four years, driven by a surge in its pharmaceutical sector, particularly Novo Nordisk. The country’s gross domestic product rose by 2.3% in the third quarter, according to global media reports, marking a significant acceleration in economic activity.
Preliminary data from Statistics Denmark reveals that the growth was largely fueled by increased production and exports of pharmaceuticals. Without the contribution of this sector, the Danish economy would have grown by only 0.7% during the same period. This highlights the increasing importance of the pharmaceutical industry to Denmark’s overall economic performance.
“The growth of the pharmaceutical industry is heavily dominated by Novo Nordisk, so there’s no doubt the company had a powerful effect on GDP in the third quarter,” noted Las Olsen, chief economist at Danske Bank.
The strong performance underscores a trend that has been developing over the past several years. Denmark has emerged as a key and rapidly expanding hub in Europe, bolstered by the remarkable success of diabetes and weight-loss drugs Ozempic and Wegovy.
Denmark’s exports increased by 4.1% in the third quarter alone, a figure directly linked to the pharmaceutical sector’s output and rising sales of chemical products. The statistical agency indicated that this growth reflects expanded production capacity and lower manufacturing costs within the industry.
Novo Nordisk Faces Increasing Competition
Despite its current dominance, Novo Nordisk is operating in an increasingly competitive environment. In the crucial U.S. market, Eli Lilly is aggressively expanding its market share with drugs like Mounjaro and Zepbound, which, though launched later than Novo Nordisk’s products, are already impacting the competitive landscape.
Increased pressure in the U.S. led Novo Nordisk to lower its full-year forecasts, initiate a restructuring program, and plan for workforce reductions of more than 10% globally under new CEO Mike Dustdar.
This coincided with price adjustments for Ozempic and Wegovy, which were reduced to $349 for the lowest dose after the company, along with Eli Lilly, reached an agreement with the Trump administration for more affordable pricing.
Novo Nordisk’s market capitalization currently stands at 1.4 trillion Danish kroner (€187.5 billion), with third-quarter sales exceeding 70 billion kroner (€9.4 billion). While the company’s stock has lost nearly half its value since the beginning of the year, underlying business activity remains strong.
Shifting Focus
According to economist Lars Christensen, there is a “slight disconnect” between the company’s conservative messaging and its actual results. He emphasized that “regarding management, cuts, and the share price, there is unnecessary noise,” but that tracking real investments and capacity expansion reveals a “undoubtedly positive” impact on the Danish economy.
This influence is significant enough that Danish exports grew by over 13% in 2023, and consensus forecasts predict another increase of approximately 7.4% in 2024. Novo Nordisk is among the largest corporate taxpayers in the country, contributing around €3 billion last year – more than double the amount from four years prior. Without the company’s substantial contribution, Denmark’s GDP growth of 1.9% in 2023 would have been nearly zero.
This reliance, however, also raises questions about sustainability. Many economists draw parallels to the Finnish crisis surrounding Nokia in the late 2000s, when the decline of the technology giant contributed to half of the 2009 collapse in Finland’s GDP.
Similarly, a significant portion of Novo Nordisk’s revenue comes from a relatively narrow product range, and competition from U.S. and other pharmaceutical companies is intensifying. Analysts caution that Denmark should leverage its current record revenues to develop a broader pharmacological ecosystem and invest in other economic sectors.
Goldman Sachs points out that despite growing competition, Novo Nordisk’s position remains strong thanks to investments in production and compelling clinical data. They believe that Wegovy, which not only aids weight loss but also reduces the risk of cardiovascular disease, provides the company with a “key competitive advantage.”
While Denmark’s overall economy remains near stagnation, the growth of Novo Nordisk is “pushing up overall activity levels” as other industries and construction contract, according to analysts at Danske Bank.
